Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus
This clinical study has two major contributions. First, it showed that systemic treatment with the natural Gene-Eden-VIR/Novirin decreased the time to HPV clearance, increased the percentage of HPV-free individuals, and caused no adverse experiences in individuals suffering from a symptomatic HPV infection. Since there are no other systemic treatments for symptomatic HPV infections, this study presents highly valuable information on the clinical effects of the first treatment in this category. Second, the study presents a new method for conducting clinical studies that addresses one of the major deficiencies associated with the practice of the randomized controlled trial method.
3-Econsystems: MicroRNAs, Receptors, and Latent Viruses; Some Insights Biology Can Gain from Economic Theory
This mini-review describes three biological systems. All three include competing molecules and a limiting molecule that binds the competing molecules. Such systems are extensively researched by economists. In fact, the issue of limited resources is the defining feature of economic systems.
Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir
The clinical study showed that the natural Gene-Eden-VIR/Novirin decreases the number of genital herpes outbreaks without any side effects. The study also showed that the clinical effects reported in this study are mostly better than those reported in the reviewed studies of acyclovir, valacyclovir, and famciclovir.
Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases
This paper shows that suppressive treatment with Gene-Eden-VIR/Novirin decreased the duration of genital herpes outbreaks, in both severe and mild cases, without any side effects.
Commentary: The unliganded glucocorticoid receptor positively regulates the tumor suppressorgene BRCA1 through GABP beta.
This commentary explains how stress can increase microcompetition between a viral promoter/enhancer and the BRCA1 gene, and decrease the expression of the BRCA1 gene.
Microcompetition with latent Epstein-Barr virus causes a transcription factor deficiency, under-expression of retinoblastoma, and classic Hodgkin lymphoma
Classic Hodgkin Lymphoma (cHL) is characterized by the presence of Hodgkin/Reed-Sternberg (H/RS) cells, the malignant cells of the tumor.1 H/RS cells show two kinds of changes in their retinoblastoma (pRb) tumor suppressor, inactivation through hyper-phosphorylation of the protein, and low concentration caused by under-expression or over-degradation. This commentary concentrates on the under-expression option.
The latent cytomegalovirus decreases telomere length by microcompetition
Latent CMV infection may cause reduced telomere length via GABP transcription factor deficiency, according to the Microcompetition Theory. Microcompetition and viral-induced transcription factor deficiency is important since most people harbor a latent viral infection.
Latent Viruses, Microcompetition, Transcription Factor Deficiency and the Cause of Acute Lymphoblastic Leukemia
We would like to propose a different event that might cause such deficiency. This event is the presence of certain latent viruses in infected cells. The event and its molecular, cellular and clinical consequences have been described by Hanan Polansky in 2003 in his book on Microcompetition.
Gene-Eden, a broad range, natural antiviral supplement, may shrink tumors and strengthen the immune system
According to the Microcompetition theory, latent viruses can cause pancreatic cancer, and an antiviral supplement that targets latent viruses can be effective in treating the disease. Gene-Eden-VIR is a promising broad range, natural antiviral supplement that targets latent viruses. The results of this case study show that the addition of Gene-Eden-VIR to chemotherapy may have participated in shrinking the tumor and in strengthening the immune system in a case with poor prognosis. Such participation is consistent with the expected effects of Gene-Eden-VIR on pancreatic cancer according to the Microcompetition theory.
Gene-Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory
This post marketing clinical study showed that treatment with Gene-Eden-VIR safely decreased the feeling of general, physical, and mental fatigue in individuals infected with a latent virus. Since most individuals are infected with a latent virus, health care practitioners should recommend Gene-Eden-VIR as a first line treatment for fatigue. The results of this post marketing clinical study support the Microcompetition with Foreign DNA theory.
Belief change as change in epistemic entrenchment
In this paper, it is argued that both the belief state and its input should be represented as epistemic entrenchment (EE) relations. A belief revision operation is constructed that updates a given EE relation to a new one in light of an evidential EE relation, and an axiomatic characterization of this operation is given. Unlike most belief revision operations, the one developed here can handle both “multiple belief revision” and “iterated belief revision”.
Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study
This paper reports the results of a post marketing clinical study that tested the antiviral properties of Gene-Eden-VIR. Specifically, the clinical study tested the effect of Gene-Eden-VIR on the severity, duration, and frequency of symptoms reported by individuals infected with various viruses.